The peripheral and central nervous, cardiovascular and respiratory effects of midazolam 0.15 mglkg, administered intravenously, were studied in 57 patients. Midazolam induced anaesthesia satisfactorily in 78% of the patients, the remainder required either further doses of midazolam, or alternative induction agents. There was no pain on injection. No evidence of thrombophlebitis was apparent up to 72 hours after injection. Mean systolic arterial pressure decreased from 128 mm Hg to 114 mm Hg and mean diastolic pressure decreased from 75 mm Hg to 67 mm Hg (P < 0.005) four minutes after injection. Mean heart rate increased from 81 beatslmin to 88 beatslmin (P < 0.005) one minute after injection. Apnoea occurred in 14 patients, with a mean onset time of 82 sec and a mean duration of 30 sec. Patients showed a decrease in mean respiratory rate from 13.7 breathslmin to 12.8 breathslmin two minutes after injection of midazolam. A larger dose than used in this study would be necessary for satisfactory use of midazolam as an induction agent for general anaesthesia.
This trial assesses the efficacy of an intravenous dose of 0.15 mg/kg of midazolam as an induction agent for anaesthesia. ROD BABER ET AI.
METHOD

Patient Selection
Suitable patients were selected from routine operating lists. On the evening before surgery the trial was explained in detail to each patient. Written consent was obtained from those patients who agreed to enter the trial.
All patients were between 20 and 60 years of age, and in good health (AS A 1-11).
Patient Exclusions
1. Patients requiring an operation lasting longer than four hours. 2. Female patients requiring caesarean section or in whom the possibility of pregnancy could not be excluded. 3 . Patients with known allergies to benzodiazepines. 4. Patients receiving long-term treatment with psychotropic agents. 5. Patients with central nervous system disease or requiring a neurosurgical operation. 6. Chronic alcoholics.
Concurrent Medications
Hypnosedatives were not given for 48 hours before the operation, except as stated below.
Drug Administration Plan
1. On the evening before the operation an oral dose of diazepam, nitrazepam or flunitrazepam was given. 2. Premedication consisted of pethidine 1 mg/kg intramuscularly (IMI) to the nearest 50, 75 or 100 mg together with atropine 0.5 mg IMI one hour before induction. 3. An intravenous cannula was placed in a forearm vein and a 23G scalp vein needle inserted into a vein on the back of the contralateral hand. 4. A mercury strain gauge, fixed across the patient's chest, monitored respiratory movements on a chart recorder.
Electrocardiograph (ECG) leads
(modified V5) were applied to the patients and the ECG recorded on cassette tape via a modem (Regional Biomedical Engineering Service, Royal North Shore Hospital), a device which places several channels of analogue signal with frequency modulation on to cassette tape. The ECG was also continuously displayed and observed on a clinical monitor (Datascope 850). 6. A blood pressure cuff was attached to the patient's arm on the same side as the intravenous cannula and the arterial pressure and pulse rate recorded each minute during the trial, using an automatic arterial pressure monitor (Dynamap 845) and recorder (Dynamap 950). * 7. The patient received oxygen via a Hudson mask (6 lImin) for 3 minutes before induction and during this time awake control measurements of arterial pressure, pulse rate, ECG and respiratory rate were made. 8. Midazolam was then injected through the scalp vein needle over 30 seconds and flushed through the vein with normal saline 5 ml. The scalp vein, having been used only for the injection of midazolam, was withdrawn immediately and a pressure dressing applied. The calculated dose of midazolam was injected undiluted from a 5 ml syringe with the dose read to an accuracy of 0.1 ml (equivalent to 0.25 mg of drug). 9. Heart and respiratory rates and arterial pressure were recorded for 3 minutes from the beginning of the injection of the midazolam. 10. After 4 minutes the muscle relaxant was injected. Both the agent used (either alcuronium or pancuronium) and the dose were at the discretion of the investigator. Anaesthesia was maintained with nitrous oxide/oxygen with or without halothane or enflurane as determined by the individual investigator . 11. The timing, in seconds of the following events was noted: 1. spontaneous closure of the eyes, 2. loss of the lid reflex, 3. apnoea (absence of respiration for 10 sec or more), and 4. inability to obey a spoken command.
The protocol allowed that should the arterial pressure increase or decrease by more than 300/0 of the control value, the investigator could intervene, via any means suitable, to restore haemodynamic stability.
If the palpebral reflex was still present 3 to 4 minutes after the first injection of midazolam, a second dose of midazolam could be given. This second dose was 50% of the first dose and was given over 15 seconds through the intravenous cannula.
Overall assessment of the drug was based on observations listed above together with postoperative visits conducted one hour after the operation and 1, 2 and 3 days after the operation. During these visits patients were asked to report any incidence of nausea, vomiting, hallucinations, dysphoria, amnesia or pain at the injection site. As well, the injection site was examined for any evidence of phlebitis.
The patient's own evaluation of the anaesthetic was sought with particular reference to the induction phase.
Standard laboratory haematology and biochemical tests were conducted on each patient.
Any adverse reactions were noted. Comparisons were made using the Student t-test.
RESULTS
Fifty-seven patients were entered into the trial. Of these 21 were males and 36 females ranging in age from 20 to 59 years. Table 1 gives a summary of patient age, height and weight.
Age (years) Height (cm) Weight (kg) Of the 57 patients studied, 44 (77%) were assessed, after the initial dose of midazolam, as having been anaesthetised, as shown by failure to respond to command and loss of palpebral reflex. The times, in seconds, for spontaneous closure of the eyes, failure to respond to command, and loss of palpebral reflex are shown in Table 2 . Respiratory changes following the administration of midazolam showed considerable variation (Table 3) . Respiratory rates showed a mean decrease of 15 % and a range from a 44% increase to a 73% decrease, as measured over one minute intervals. These percentage changes were the maximum observed during the four-minute observation period. Apnoea was seen in 14 patients (25%) ranging in duration from 12 to 70 seconds (mean 30 sec) and occurring between 40 and 136 seconds (mean 82 sec) after the drug was given. As a result of pre-oxygenation no patient with apnoea required assisted ventilation. Due to technical difficulties respiratory changes were not monitored in one patient.
In Figure 2 mean respiratory rate is plotted against time.
The maximum cardiovascular changes following the administration of midazolam are shown in Table 4 . Systolic pressure showed a mean decrease of 12%. All but one patient fell within a range of 8% increase to a 23% decrease. The remaining patient showed a 48% drop in systolic pressure which occurred 3 minutes after injection and lasted two minutes. No intervention was required to restore haemodynamic stability. Heart rate showed a mean increase of 3010, with a range of 24% increase to 17% decrease. The time course of cardiovascular effects of midazolam are shown in Figures 3 and 4 . The mean systolic and diastolic arterial pressures decreased 4 minutes after the injection from 128 (sem 2) mm Hg to 114 (sem 3) mm Hg and 75 (sem 1) mm Hg to 67 (sem 2) mm Hg respectively (P < 0.005). The mean heart rate increased 1 minute after injection, from 81 (sem 2) beats/min to 88 (sem 3) beats/min (P < 0.005) and remained elevated for the period of observation.
As noted earlier, 13 patients required a second dose of midazolam to induce anaesthesia. Five of these patients had shown no response to the initial dose, as gauged by closure of eyes, loss of palpebral reflex and response to command, whilst six had undergone spontaneous closure of the eyes, two had lost their palpebral reflex and one lost the ....... ability to respond to command. Following administration of the second dose of midazolam, ten of the thirteen patients responded with rapid closure of the eyes failure to respond to commands and loss of palpebral reflex. Three patients did not respond to this second dose of midazolam and required gaseous induction with nitrous oxide and halothane.
No changes were observed in ECG rhythm. Haematological and biochemical profiles performed on the following day were all normal.
Immediately after induction, the participating anaesthetist was asked to evaluate midazolam as an induction agent. The results Anaesthesia and Intensive Care, Vol. X, No. 1, February, 1982 are shown in Table 5 . Overall, anaesthetists rated the induction as good or very good in 73070 of cases, although only in 9% of the cases was midazolam considered better than their usual induction agent. Each patient was seen at intervals of 1, 24, 48 and 72 hours. At these visits the site of injection was examined and the presence of any symptoms referable to the anaesthetic were sought. There was no report of pain on injection and no patient experienced hallucinations or dysphoria. Injection sites were not sore, red or swollen and, there was no evidence of thrombophlebitis. There was no retrograde amnesia. All patients experienced an anterograde amnesic effect from the time of injection up to the time of awakening in the recovery ward. Nausea and vomiting were reported in 42% and 40% of cases respectively, the most common time being 24 hours after surgery ( Table 6 ).
Other side effects noted during the trial included: 1. One patient was slow to respond after the operation and eventually required physostigmine 1 mg intravenously to facilitate her recovery. 2. One patient developed ataxia 48 hours after operation. 3. Four patients developed hiccups during the induction which in one persisted intermittently during inhalational maintenance of anaesthesia. At the conclusion of the 72 hours monitoring period, patients were asked for their assessment of the total anaesthetic and the induction phase (Table 7) . Fifty-nine per cent (n = 54) described their anaesthetic as "very good", 32% as "good" and 9% as "fair". None graded the anaesthetic as "poor". Three patients did not provide an assessment of their induction. Note that patients who failed to lose consciousness did not recall the event and ultimately graded the anaesthetic favourably. 
DISCUSSION
The dose used in this trial, namely 0.15 mg/kg has been established by earlier workers 2 ,3 to be the ED50 for induction of general anaesthesia while breathing room air. We had a 78% success rate with this dose following pethidine/atropine premedication.
The wide range of times recorded for spontaneous closure of the eyes, failure to respond to command and loss of the palpebral reflex illustrates the variability of the response of patients to benzodiazepines and may also be partly attributable to the low dose used. 4 -6 Our results support the view 4 ,7,8 that midazolam has only a mild respiratory depressant effect. No patient required assisted ventilation during the procedure. Hiccups were seen in four patients, all of whom had arrived at theatre nervous and unsettled.
Our results support the belief that haemodynamic changes after midazolam are slight. 4,7-10 In those patients who did not receive a muscle relaxant and were not intubated and who could therefore be monitored for longer periods without the influence of added factors, we noted that these changes were of short duration.
There was no evidence of pain on injection or of postoperative venous irritation as sometimes occurs when diazepam is given intravenously. 2.7,9,11 Midazolam's water solubility appears to have rendered it free of these problems which may be due to the polypropylene glycol used to dissolve diazepam. 12 ,13 Anterograde amnesia has been reported 4 ,5,11,14 and all our patients exhibited anterograde amnesia beginning soon after the commencement of injection. No patient who required a second dose could remember that event. Two of the three patients who failed to lose consciousness following the second dose later rated their anaesthetic as excellent while the remaining patient rated it as good.
The amnesic effect of the drug subsided once the patient had awakened in the postoperative period. A few patients were unable to recall events happening in the ward later in the day, suggesting persisting amnesia. No such amnesia was seen on the first postoperative day or thereafter. Once patients awoke in recovery their level of consciousness continued to increase.
The overall incidence of nausea and vomiting (41070 and 40%) was slightly higher than the 30% figure reported with thiopentone-induced general anaesthesia. 15 Other reports in the literature suggest the incidence of nausea and vomiting following the use of midazolam is much lower. 4, 5, 9 The patient who was slow to recover and required physostigmine had shown identical behaviour when given a general anaesthetic at another hospital on a previous occasion.
One patient developed ataxia which was first reported 48 hours postoperatively. It is most likely that this ataxia existed from the onset but was not noted by the patient until attempting to walk. Unfortunately, this ataxia was treated with oral diazepam. The ataxia increased and only then did this patient recall being ataxic after nitrazepam several years previously. On withdrawal of the diazepam the patient recovered fully within 72 hours. We concluded that this patient showed a rare side effect of benzodiazepines.
Three patients failed to lose consciousness. One of these was a reformed drug addict and the other two arrived at theatre inadequately premedicated. The dose of midazolam used was obviously inadequate for these patients.
Overall, anaesthetists rated the induction as good or very good. The major complaint by anaesthetists was the uncertainty of response seen with the dose being used. The slower onset of effect was a lesser complaint.
Patients found the induction phase pleasant. Loss of consciousness was described as a gradual and relaxing process and without the sudden onset of many other induction agents. Those patients who had recently experienced induction with thiopentone rated midazolam above that agent. A number of patients also felt that their awakening was a more gradual process.
